Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
Journal of Personalized Medicine · 07.02.2024 · 14 (2) · 186
DOI: 10.3390/jpm14020186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 07.02.2024. Verfasst von Giovanni Fiorillo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Psoriasis can have a significant impact on quality of life and productivity, especially with increased severity. However, there is limited evidence on biologics’ efficacy in highly severe cases compared to moderate-to-severe ones. This study aimed to evaluate the effectiveness and safety of novel biological therapies in very severe psoriasis. We conducted a retrospective analysis on patients ≥ 18 years old affected by very severe psoriasis who had received a biological agent for at least 16 weeks. We used PASI to assess disease severity and effectiveness at weeks 16, 52, 104, and 156. Safety was evaluated by tracking treatment discontinuation rates and adverse events. This study included 29 males and 11 females, with a mean age of 55.80 years (SD 13.82). Cardiometabolic diseases were the most common comorbidities (25.00%). Twenty-eight (70.00%) patients had psoriasis involvement in at least one difficult-to-treat area. All patients completed 16 weeks of treatment. The mean PASI was 31.60 (SD 2.57) at baseline, 3.48 (SD 4.13) at week 16, 0.58 (SD 1.70) at week 52, 0.77 (SD 1.66) at week 104, and 1.29 (SD 2.12) at week 156. PASI90 and 100 were achieved by 52.50% and 30.00% of patients at week 16, by 96.15% and 80.77% at week 52, by 93.33% and 66.67% at week 104, and by 85.71% and 42.86% at week 156. PASIs ≤ 2 were achieved by 50.00% of patients at week 16, 88.46% at week 52, 86.67% at week 104, and 85.71% at week 156. Only two patients discontinued biologics due to complete remission, and mild AEs were reported by four patients. Our findings show that biologics are effective and well tolerated for treating very severe psoriasis, maintaining long-term effectiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
- Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
ORCID-Profile: Giovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, Mario Valenti
Zitieren
APA
Fiorillo, G., Ibba, L., Gargiulo, L., Narcisi, A., Costanzo, A., & Valenti, M. (2024). Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. Journal of Personalized Medicine, 14(2), 186. https://doi.org/10.3390/jpm14020186
Vancouver
Fiorillo G, Ibba L, Gargiulo L, Narcisi A, Costanzo A, Valenti M. Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. Journal of Personalized Medicine. 2024;14(2):186. doi:10.3390/jpm14020186
BibTeX
@article{Fiorillo2024,
author = {Fiorillo, Giovanni and Ibba, Luciano and Gargiulo, Luigi and Narcisi, Alessandra and Costanzo, Antonio and Valenti, Mario},
title = {Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {2},
pages = {186},
doi = {10.3390/jpm14020186}
}
EUVIMED